Baxter Q4 Preview: Analysts See 2.2% Revenue Gain to $2.81B, $0.54 EPS
Baxter reported Q3 revenue of $2.84 billion, up 5% year-over-year but missed forecasts by 1.4% and fell short on full-year EPS guidance. Analysts forecast Q4 revenue growth of 2.2% to $2.81 billion with adjusted EPS of $0.54, after Baxter missed estimates in six of the past eight quarters.
1. Q3 Performance and Guidance Miss
Baxter’s Q3 generated $2.84 billion in revenue, a 5% year-over-year increase, yet fell 1.4% short of analyst projections. The company also missed its own full-year EPS guidance, marking six revenue estimate misses in the past two years.
2. Q4 Analyst Projections
For Q4, analysts predict revenues of $2.81 billion, a 2.2% increase versus last year, and adjusted earnings of $0.54 per share. Consensus estimates have remained largely unchanged over the past 30 days, indicating steady expectations heading into the report.
3. Operational Challenges and Peer Context
Baxter continues to face headwinds in its Infusion Therapies & Technologies division, including a hold on the Novum IQ pump and US IV fluid conservation trends. Peers Neogen and Stryker reported mixed Q4 results—Neogen’s revenues dipped 2.8% but beat estimates by 7.2%, while Stryker grew 11.4%—as the diversified medical devices group underperformed, down 3.7% on average over the last month.